Under construction – not a live service

Skip to content

Frontlight Research

Institution

National Cancer Center

Goyang-si, South KoreaWebsite

Also known as: 국립암센터 · NCC

250running trials
85closed trials
1researcher
14,032publications (OpenAlex)

Researchers

Jeongseon Kim

Running trials

Not yet recruiting
Robotic Bronchoscopy for Small Lung Nodules Without a Bronchus Sign
NCT07862816· Intuitive Surgical· Source
Not yet recruiting
Edoxaban Versus Apixaban in Cancer-Associated Venous Thromboembolism
NCT07852637· Phase 4· Samsung Medical Center· Source
Recruiting
A Study of Ramantamig Plus Daratumumab Versus Daratumumab, Bortezomib, Lenalidomide, and Dexamethasone (DVRd) or Daratumumab, Lenalidomide, and Dexamethasone (DRd) in Participants With NDMM For Whom Stem Cell Transplant is Not Planned
NCT07665450· Phase 3· Janssen Research & Development, LLC· Source
Recruiting
BL-M14D1 Plus Atezolizumab vs Standard of Care in First-Line Extensive-Stage Small Cell Lung Cancer (BrenDeLL-Lung01)
NCT07625644· Phase 3· SystImmune Inc.· Source
Recruiting
Treatment Patterns and Survival Outcomes in High-Grade Osteosarcoma: A Multicenter Retrospective Study
NCT07878364· MedPacto, Inc.· Source
Recruiting
A Clinical Trial of Calderasib (MK-1084) and Durvalumab in People With Non-Small Cell Lung Cancer (MK-1084-015/KANDLELIT-015)
NCT07554339· Phase 3· Merck Sharp & Dohme LLC· Source
Active, not recruiting
Muco-active Agent Use and Clinical Outcomes After Lung Cancer Diagnosis in Chronic Obstructive Pulmonary Disease
NCT07712016· Seoul National University· Source
Recruiting
A Study Comparing JNJ-79635322 and Teclistamab in Participants With Relapsed or Refractory Multiple Myeloma
NCT07518186· Phase 3· Janssen Research & Development, LLC· Source
Recruiting
RO7771950 Versus Tucatinib in Combination With Trastuzumab and Capecitabine in People With Locally Advanced or Metastatic Breast Cancer That is Human Epidermal Growth Factor Receptor 2 (HER2)-Positive
NCT07413939· Phase 2/3· Hoffmann-La Roche· Source
Recruiting
A Study of Precemtabart Tocentecan With or Without Bevacizumab Compared to Trifluridine/Tipiracil Plus Bevacizumab in Participants With Previously Treated Metastatic Colorectal Cancer (PROCEADE-CRC-03)
NCT07549412· Phase 3· EMD Serono Research & Development Institute, Inc.· Source
Recruiting
A Clinical Trial of Adjuvant Intismeran (V940) With or Without Pembrolizumab Coformulated With Berahyaluronidase Alfa (MK-3475A) in High-Risk Stage I Non-Small Cell Lung Cancer (V940-014)
NCT07513376· Phase 3· Merck Sharp & Dohme LLC· Source
Recruiting
DAREON ® -Lung-1: A Study in People With Advanced Small Cell Lung Cancer to Compare Obrixtamig Plus Atezolizumab, Carboplatin, and Etoposide Treatment With Standard Chemoimmunotherapy
NCT07472517· Phase 3· Boehringer Ingelheim· Source
Recruiting
A Clinical Trial of Ifinatamab Deruxtecan in People With Advanced Esophageal Cancer (MK-3475-06F)
NCT07405151· Phase 1/2· Merck Sharp & Dohme LLC· Source
Recruiting
MK-3475A±Calderasib (MK-1084) in Completely Resected Stage IIA-IIIB (N2) KRAS G12Cm NSCLC (MK-1084-013)
NCT07431827· Phase 3· Merck Sharp & Dohme LLC· Source
Recruiting
A Study to Evaluate the Efficacy and Safety of Standard-of-Care Chemotherapy and Bevacizumab With or Without INCA33890 in the First-Line Treatment of Metastatic Microsatellite Stable Colorectal Cancer
NCT07284849· Phase 3· Incyte Corporation· Source
Recruiting
A Phase 3 Study of [177Lu]Ludotadipep for Metastatic Castration-Resistant Prostate Cancer
NCT07853209· Phase 3· FutureChem· Source
Recruiting
Argon Plasma Coagulation Versus Endoscopic Mucosal Resection for Gastric Adenoma (CLER-GA)
NCT07161479· Samsung Medical Center· Source
Recruiting
A Clinical Study of Sacituzumab Tirumotecan (MK-2870) in Combination With Pembrolizumab (MK-3475) as First-line Maintenance Treatment of Cervical Cancer (MK-2870-036/TroFuse-036/GOG-3123/ENGOT-cx22)
NCT07216703· Phase 3· Merck Sharp & Dohme LLC· Source
Recruiting
Beamion LUNG-3: Adjuvant Zongertinib vs Standard Treatment in People With Completely Resected Stage II-IIIB NSCLC Harboring Activating HER2 TKD Mutations
NCT07195695· Phase 3· Boehringer Ingelheim· Source
Recruiting
A Study to Compare the Combination of Navlimetostat (BMS-986504) With Pembrolizumab and Chemotherapy Versus Placebo Plus Pembrolizumab and Chemotherapy in First-line Metastatic Non-small Cell Lung Cancer Participants With Homozygous MTAP Deletion
NCT07063745· Phase 2/3· Bristol-Myers Squibb· Source
Recruiting
A Study to Evaluate the Safety and Efficacy of Pumitamig in Combination With Chemotherapy Versus Bevacizumab in Combination With Chemotherapy in Participants With Previously Untreated, Unresectable, or Metastatic Colorectal Cancer
NCT07221357· Phase 2/3· Bristol-Myers Squibb· Source
Recruiting
A Study to Assess Zipalertinib Versus Placebo in Participants With Early Stage NSCLC With Uncommon EGFR Mutations, Following Complete Tumor Resection
NCT07128199· Phase 3· Taiho Oncology, Inc.· Source
Recruiting
A Study of Pasritamig With Docetaxel Versus Docetaxel in Participants With Metastatic Castration-Resistant Prostate Cancer
NCT07225946· Phase 3· Janssen Research & Development, LLC· Source
Recruiting
Study to Assess the Effect of OCT-598 in Patients With Advanced Solid Tumors
NCT07358806· Phase 1· Oscotec Inc.· Source
Recruiting
The KN510713 Study in Combination With mFOLFIRINOX
NCT07114861· Phase 1/2· New Cancer Cure-Bio Co.,Ltd.· Source
Recruiting
A Study of Intismeran Autogene (V940)/Placebo + Pembrolizumab and Chemotherapy in Metastatic Squamous Non-Small Cell Lung Cancer (V940-013)
NCT07221474· Phase 2· Merck Sharp & Dohme LLC· Source
Recruiting
A Study of Vepugratinib (LY3866288) in Participants With Cancer in the Urinary Tract
NCT07218380· Phase 3· Eli Lilly and Company· Source
Recruiting
A Study to Assess Adverse Events and Change in Disease Activity of Intravenous (IV) Telisotuzumab Adizutecan, Monotherapy or in Combination With Osimertinib, Compared to Standard of Care in Adult Participants With Locally Advanced or Metastatic EGFR-Mutated Non-Squamous Non-Small Cell Lung Cancer
NCT07155187· Phase 2/3· AbbVie· Source
Recruiting
A Study to Evaluate the Optimal Dose, Adverse Events and Change in Disease Activity of Intravenous ABBV-706 in Combination With Atezolizumab Versus Standard of Care as First-Line Treatment in Adult Participants With Previously Untreated Extensive Stage Small Cell Lung Cancer
NCT07155174· Phase 2· AbbVie· Source
Recruiting
A Study to Assess Adverse Events and Change in Disease Activity of Multiple Treatment Combinations With Intravenous Mirvetuximab Soravtansine in Adult Participants With Ovarian Cancer
NCT07059845· Phase 2· AbbVie· Source
Recruiting
ROSETTA Breast-01: The Effects and Safety of Pumitamig in Patients With Triple-Negative Breast Cancer
NCT07173751· Phase 3· BioNTech SE· Source
Recruiting
Study of Trastuzumab Deruxtecan, Pembrolizumab, and Platinum-based Chemotherapy in First-line HER2 Overexpressing Non-small Cell Lung Cancer
NCT06899126· Phase 3· Daiichi Sankyo· Source
Recruiting
A Three-Part Phase 3 Study of Sofetabart Mipitecan in Participants With Platinum-Resistant (Part A) and Platinum-Sensitive (Parts B and C) Ovarian Cancer
NCT07213804· Phase 3· Eli Lilly and Company· Source
Recruiting
A Study to Learn About the Study Medicine Called PF-08046054/SGN-PDL1V Versus Docetaxel in Adult Participants With Previously-Treated Programmed Cell Death Ligand 1 (PD-L1) Positive Non-Small-Cell Lung Cancer (NSCLC)
NCT07144280· Phase 3· Pfizer· Source
Recruiting
This Study Will Explore Whether a Combination of the Investigational Drug Mevrometostat (PF-06821497) and Enzalutamide Will Work Better Than Taking Enzalutamide Alone in Participants With mCSPC Who Are ARPI naïve.
NCT07028853· Phase 3· Pfizer· Source
Enrolling by invitation
Patients With High-grade Pancreatic Neuroendocrine Tumors
NCT07121478· Phase 2· National Cancer Center, Korea· Source
Recruiting
Secondary Cytoreductive Surgery After Chemotherapy for Recurrent Epithelial Ovarian Cancer
NCT07171528· Phase 2· National Cancer Center, Korea· Source
Recruiting
A Study of Pasritamig With or Without JNJ-87189401 Versus Placebo for Late Line Metastatic Castration-resistant Prostate Cancer (mCRPC)
NCT07164443· Phase 3· Janssen Research & Development, LLC· Source
Not yet recruiting
Intravesical Hyaluronic Acid (HA) for Preventing Radiation Cystitis on Bladder Cancer
NCT07125924· National Cancer Center, Korea· Source
Active, not recruiting
A Study Comparing Tarlatamab, Durvalumab, Carboplatin, and Etoposide Versus Durvalumab, Carboplatin, and Etoposide in First-line Extensive Stage Small-Cell Lung Cancer (ES-SCLC)
NCT07005128· Phase 3· Amgen· Source
Recruiting
A Study to Learn About the Study Medicine Called PF-07248144 in Combination With Fulvestrant in People With HR-positive, HER2-negative Advanced or Metastatic Breast Cancer Who Progressed After a Prior Line of Treatment.
NCT07062965· Phase 3· Pfizer· Source
Recruiting
Substudy 06E: Umbrella Study of Combination Therapies in Esophageal Cancer (MK-3475-06E/KEYMAKER-U06)
NCT06780111· Phase 1/2· Merck Sharp & Dohme LLC· Source
Recruiting
Phase 3 Study of Gedatolisib as First-Line Treatment for Patients With HR-Positive, HER2-Negative Advanced Breast Cancer (VIKTORIA-2)
NCT06757634· Phase 3· Celcuity Inc· Source
Recruiting
Evaluation of Two Dose Levels of Quizartinib as Maintenance in FLT3-ITD (+) Acute Myeloid Leukemia Patients in Complete Remission
NCT06824168· Phase 2· Daiichi Sankyo· Source
Recruiting
Neladalkib (NVL-655) for TKI-naive Patients With Advanced ALK-Positive NSCLC
NCT06765109· Phase 3· Nuvalent Inc.· Source
Recruiting
A Clinical Study of Calderasib (MK-1084) With Targeted Therapy and Chemotherapy in People With Colorectal Cancer (MK-1084-012/KANDLELIT-012)
NCT06997497· Phase 3· Merck Sharp & Dohme LLC· Source
Recruiting
A Clinical Study of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) in People With Breast Cancer (MK-2870-032)
NCT06966700· Phase 3· Merck Sharp & Dohme LLC· Source
Recruiting
Streamlining Radioembolization for CCC and Metastatic Liver Cancer
NCT07043387· Seoul National University Hospital· Source
Recruiting
Effectiveness of ERAS on Postoperative Recovery After Minimally Invasive Gastrectomy
NCT06984952· Seoul National University Hospital· Source
Recruiting
Streamlining Radioembolization for Small HCC
NCT06979219· Seoul National University Hospital· Source

Showing 50 of 250.

Recruiting at the same time

How many trials recruit for the same indication here at once. A count, not a rating.

Lung cancer39 recruiting
Ovarian cancer17 recruiting
Colorectal cancer14 recruiting
Gastric and oesophageal cancer13 recruiting
Liver and biliary tract cancer11 recruiting
Pancreatic cancer11 recruiting
Childhood cancers9 recruiting
Head and neck cancer8 recruiting
Prostate cancer8 recruiting
Bladder cancer7 recruiting
Cervical cancer6 recruiting
Endometrial cancer6 recruiting
Metastatic breast cancer6 recruiting
Triple-negative breast cancer6 recruiting
Acute myeloid leukaemia2 recruiting
Diffuse large B-cell lymphoma2 recruiting
Melanoma2 recruiting
Multiple myeloma2 recruiting
Sarcoma2 recruiting
Chronic lymphocytic leukaemia1 recruiting
Hepatitis B1 recruiting
Kidney cancer1 recruiting
Neuroendocrine tumours1 recruiting
Thyroid cancer1 recruiting

Closed trials

Recruiting
Study to Evaluate INCB123667 Versus Investigator's Choice of Chemotherapy in Participants With Platinum-Resistant Ovarian Cancer With Cyclin E1 Overexpression
NCT07214779· Phase 3· Incyte Corporation· Source
Terminated
Streamlining Radioembolization for Intrahepatic Cholangiocarcinoma
NCT07043348· Seoul National University Hospital· Source
Completed
Fluorescent Approach for Refined Endoscopic Marking With Clip Localization and Identification Procedure
NCT06714292· Phase 2· Seoul National University Hospital· Source
Completed
Efficacy and Safety of DKF-MA102 in Patients With Prostate Cancer
NCT06490328· Phase 3· Dongkook Pharmaceutical Co., Ltd.· Source
Completed
A Study to Evaluate LBL-007 in Combination With Tislelizumab Plus Chemotherapy in Participants With Unresectable Locally Advanced or Metastatic Esophageal Squamous Cell Carcinoma
NCT06010303· Phase 2· BeiGene· Source
Completed
A Study of Gimistotug (BGB-A445) in Combination With Other Investigational Agents in Participants With Non-Small Cell Lung Cancer
NCT06029127· Phase 2· BeiGene· Source
Completed
A Study of Tislelizumab in Combination With Investigational Agents in Participants With Head and Neck Squamous Cell Carcinoma
NCT05909904· Phase 2· BeiGene· Source
Recruiting
A Study of Zipalertinib in Patients With Advanced Non-Small Cell Lung Cancer With Epidermal Growth Factor Receptor (EGFR) Exon 20 Insertions or Other Uncommon Mutation.
NCT05967689· Phase 2· Taiho Oncology, Inc.· Source
Completed
A Study of Immune Checkpoint Inhibitor Combinations With Axitinib in Participants With Untreated Locally Advanced Unresectable or Metastatic Renal Cell Carcinoma
NCT05805501· Phase 2· Hoffmann-La Roche· Source
Terminated
Osimertinib and Locally Ablative Radiotherapy in Patients With Synchronous Oligo-metastatic EGFR Mutant NSCLC (STEREO)
NCT04908956· Phase 2· ETOP IBCSG Partners Foundation· Source
Completed
A Study of TAR-200 in Combination With Cetrelimab and Cetrelimab Alone in Participants With Muscle-Invasive Urothelial Carcinoma of the Bladder
NCT04919512· Phase 2· Janssen Research & Development, LLC· Source
Terminated
A Study Evaluating Bemarituzumab in Combination With Other Anti-cancer Therapies in Subjects With Previously Untreated Advanced Gastric or Gastroesophageal Junction Cancer.
NCT05322577· Phase 1/2· Amgen· Source
Completed
Bemarituzumab or Placebo Plus Chemotherapy in Gastric Cancers With Fibroblast Growth Factor Receptor 2b (FGFR2b) Overexpression
NCT05052801· Phase 3· Amgen· Source
Completed
A Study of Evorpacept (ALX148) in Patients With Advanced HER2+ Gastric Cancer (ASPEN-06)
NCT05002127· Phase 2/3· ALX Oncology Inc.· Source
Terminated
Study of Magrolimab Combination Therapy in Patients With Non-Surgically Removable Locally Advanced or Metastatic Triple-Negative Breast Cancer
NCT04958785· Phase 2· Gilead Sciences· Source
Completed
A Study to Assess Efficacy of RXC004 +/- Nivolumab in Ring Finger Protein 43 (RNF43) or R-spondin (RSPO) Aberrated, Metastatic, Microsatellite Stable, Colorectal Cancer After Progression on Standard of Care (SOC)
NCT04907539· Phase 2· Redx Pharma Ltd· Source
Completed
A Study of Atezolizumab Versus Placebo as Adjuvant Therapy in Participants With High-risk Muscle-invasive Bladder Cancer (MIBC) Who Are ctDNA Positive Following Cystectomy
NCT04660344· Phase 3· Hoffmann-La Roche· Source
Completed
Trastuzumab Deruxtecan in Participants With HER2-overexpressing Advanced or Metastatic Colorectal Cancer
NCT04744831· Phase 2· Daiichi Sankyo· Source
Completed
Tisotumab Vedotin vs Chemotherapy in Recurrent or Metastatic Cervical Cancer
NCT04697628· Phase 3· Seagen, a wholly owned subsidiary of Pfizer· Source
Completed
A Study of Atezolizumab Plus Tiragolumab in Combination With Paclitaxel and Cisplatin Compared With Paclitaxel and Cisplatin as First-Line Treatment in Participants With Unresectable Locally Advanced, Unresectable Recurrent, or Metastatic Esophageal Carcinoma
NCT04540211· Phase 3· Hoffmann-La Roche· Source
Completed
Study of Atezolizumab in Combination With Cabozantinib Versus Docetaxel in Patients With Metastatic Non-Small Cell Lung Cancer Previously Treated With an Anti-PD-L1/PD-1 Antibody and Platinum-Containing Chemotherapy
NCT04471428· Phase 3· Hoffmann-La Roche· Source
Completed
ABC-lung: Atezolizumab, Bevacizumab and Chemotherapy in EGFR-mutant Non-small Cell Lung Carcinoma
NCT04245085· Phase 2· ETOP IBCSG Partners Foundation· Source
Completed
A Study of Atezolizumab and Tiragolumab Compared With Durvalumab in Participants With Locally Advanced, Unresectable Stage III Non-Small Cell Lung Cancer (NSCLC)
NCT04513925· Phase 3· Hoffmann-La Roche· Source
Terminated
A Study of Xevinapant (Debio 1143) in Combination With Platinum-Based Chemotherapy and Standard Fractionation Intensity-Modulated Radiotherapy in Participants With Locally Advanced Squamous Cell Carcinoma of the Head and Neck, Suitable for Definitive Chemoradiotherapy (TrilynX)
NCT04459715· Phase 3· EMD Serono Research & Development Institute, Inc.· Source
Completed
Study to Compare AMG 510 "Proposed INN Sotorasib" With Docetaxel in Non Small Cell Lung Cancer (NSCLC) (CodeBreak 200).
NCT04303780· Phase 3· Amgen· Source
Completed
Study of Chemoradiotherapy With or Without Pembrolizumab (MK-3475) For The Treatment of Locally Advanced Cervical Cancer (MK-3475-A18/KEYNOTE-A18/ENGOT-cx11/GOG-3047)
NCT04221945· Phase 3· Merck Sharp & Dohme LLC· Source
Completed
TTX-030 in Combination With Immunotherapy and/or Chemotherapy in Subjects With Advanced Cancers
NCT04306900· Phase 1· Trishula Therapeutics, Inc.· Source
Completed
Anti-HER2 Bispecific Antibody Zanidatamab (ZW25) Activity in Combination With Chemotherapy With/Without Tislelizumab
NCT04276493· Phase 1/2· BeiGene· Source
Completed
Study of Pembrolizumab (MK-3475) Versus Placebo in Participants With Esophageal Carcinoma Who Are Receiving Chemotherapy and Radiation Therapy (MK-3475-975/KEYNOTE-975)
NCT04210115· Phase 3· Merck Sharp & Dohme LLC· Source
Completed
A Study of Erdafitinib Versus Investigator Choice of Intravesical Chemotherapy in Participants Who Received Bacillus Calmette-Guérin (BCG) and Recurred With High Risk Non-Muscle-Invasive Bladder Cancer (NMIBC)
NCT04172675· Phase 2· Janssen Research & Development, LLC· Source
Completed
Clinical Trial of YH25448(Lazertinib) as the First-line Treatment in Patients With EGFR Mutation Positive Locally Advanced or Metastatic NSCLC (LASER301)
NCT04248829· Phase 3· Yuhan Corporation· Source
Completed
A Study to Assess the Effectiveness and Safety of Irinotecan Liposome Injection, 5-fluorouracil/Leucovorin Plus Oxaliplatin in Patients Not Previously Treated for Metastatic Pancreatic Cancer, Compared to Nab-paclitaxel+Gemcitabine Treatment
NCT04083235· Phase 3· Ipsen· Source
Completed
A Study of Atezolizumab Plus Carboplatin and Etoposide With or Without Tiragolumab in Patients With Untreated Extensive-Stage Small Cell Lung Cancer
NCT04256421· Phase 3· Hoffmann-La Roche· Source
Completed
Safety and Preliminary Effectiveness of BGB-A445 in Combination With Tislelizumab in Participants With Advanced Solid Tumors
NCT04215978· Phase 1· BeiGene· Source
Completed
TAK-788 as First-Line Treatment Versus Platinum-Based Chemotherapy for Non-Small Cell Lung Cancer (NSCLC) With EGFR Exon 20 Insertion Mutations
NCT04129502· Phase 3· Takeda· Source
Completed
Study of DF1001 in Patients With Advanced Solid Tumors
NCT04143711· Phase 1/2· Dragonfly Therapeutics· Source
Completed
A Study of Tepotinib Plus Osimertinib in Osimertinib Relapsed MET Amplified NSCLC (INSIGHT 2)
NCT03940703· Phase 2· EMD Serono Research & Development Institute, Inc.· Source
Recruiting
A Study of Tulmimetostat DZR123 (CPI-0209) in Patients With Advanced Solid Tumors and Lymphomas
NCT04104776· Phase 1/2· Novartis Pharmaceuticals· Source
Completed
Dose-Escalation and Efficacy Study of LAE001/Prednisone Plus Afuresertib Patients With m-CRPC
NCT04060394· Phase 1/2· Laekna Limited· Source
Completed
To Evaluate the Safety, Pharmacokinetics, Pharmacodynamics, and Antitumor Activity of ABN401 in Patients With Advanced Solid Tumors and Non-Small Cell Lung Cancer Harboring c-MET Dysregulation
NCT04052971· Phase 1· Abion Inc· Source
Completed
A Study of Pembrolizumab (MK-3475) With or Without Maintenance Olaparib in First-line Metastatic Squamous Non-small Cell Lung Cancer (NSCLC, MK-7339-008/KEYLYNK-008)
NCT03976362· Phase 3· Merck Sharp & Dohme LLC· Source
Completed
Study of Pembrolizumab With Maintenance Olaparib or Maintenance Pemetrexed in First-line (1L) Metastatic Nonsquamous Non-Small-Cell Lung Cancer (NSCLC) (MK-7339-006, KEYLYNK-006)
NCT03976323· Phase 3· Merck Sharp & Dohme LLC· Source
Completed
Perioperative Pembrolizumab (MK-3475) Plus Neoadjuvant Chemotherapy Versus Perioperative Placebo Plus Neoadjuvant Chemotherapy for Cisplatin-eligible Muscle-invasive Bladder Cancer (MIBC) (MK-3475-866/KEYNOTE-866)
NCT03924856· Phase 3· Merck Sharp & Dohme LLC· Source
Completed
Safety and Efficacy of Pembrolizumab (MK-3475) Versus Placebo as Adjuvant Therapy in Participants With Hepatocellular Carcinoma (HCC) and Complete Radiological Response After Surgical Resection or Local Ablation (MK-3475-937 / KEYNOTE-937)
NCT03867084· Phase 3· Merck Sharp & Dohme LLC· Source
Completed
Study Of Palbociclib Combined With Chemotherapy In Pediatric Patients With Recurrent/Refractory Solid Tumors
NCT03709680· Phase 2· Pfizer· Source
Completed
Phase 3 Trial of Elacestrant Versus Standard of Care for the Treatment of ER+/HER2- Advanced Breast Cancer
NCT03778931· Phase 3· Stemline Therapeutics, Inc.· Source
Completed
Evaluation of Efficacy and Safety of Neoadjuvant Treatment With Pamrevlumab in Combination With Chemotherapy (Either Gemcitabine Plus Nab-paclitaxel or FOLFIRINOX) in Participants With Locally Advanced, Unresectable Pancreatic Cancer
NCT03941093· Phase 3· Kyntra Bio· Source
Completed
Study of First-line Pembrolizumab (MK-3475) With Lenvatinib (MK-7902/E7080) in Urothelial Carcinoma Cisplatin-ineligible Participants Whose Tumors Express Programmed Cell Death-Ligand 1 and in Participants Ineligible for Platinum-containing Chemotherapy (MK-7902-011/E7080-G000-317/ LEAP-011)
NCT03898180· Phase 3· Merck Sharp & Dohme LLC· Source
Completed
Study of Pembrolizumab (MK-3475) Plus Olaparib Versus Abiraterone Acetate or Enzalutamide in Metastatic Castration-resistant Prostate Cancer (mCRPC) (MK-7339-010/KEYLYNK-010)
NCT03834519· Phase 3· Merck Sharp & Dohme LLC· Source
Completed
A Study of Brigatinib Compared to Alectinib in Adults With Non-Small-Cell Lung Cancer
NCT03596866· Phase 3· Takeda· Source

Showing 50 of 85.

Registry name variants (67)

Trial registries list this institution under these names. Each row is one registry entry: its address and the trials registered under it.

National Cancer Center
Goyang-si, Gyeonggi-do 10408
161 trials
National Cancer Center
Gyeonggi-do, Gyeonggi-do 10408
39 trials
National Cancer Center
Goyang, 10408
28 trials
National Cancer Center - Korea
Goyang-si, Gyeonggido [Kyonggi-do] 10408
23 trials
National Cancer Center
Goyang-si Gyeonggi-do, 10408
14 trials
National Cancer Center
Ilsandong-gu, 10408
3 trials
- NCT06561685A Study of LY4050784 in Participants With Advanced or Metastatic Solid Tumors
- NCT04306900TTX-030 in Combination With Immunotherapy and/or Chemotherapy in Subjects With Advanced Cancers
- NCT04008797A Study of E7386 in Combination With Other Anticancer Drug(s) in Participants With Solid Tumor
National Cancer Center
Seoul, 10408
3 trials
- NCT05254171Study of Nab-Paclitaxel and Gemcitabine With or Without SBP-101 in Pancreatic Cancer
  Contact: Woo Jin Lee, MD
- NCT05183984Niraparib With beVAcizumab After Complete cytoreductioN in Patients With ovArian Cancer
  Contact: Lim Myong Cheol
- NCT04585750The Evaluation of PC14586 in Patients With Advanced Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE)
  Contact: Myong Cheol Lim, MD, PhD
Clinical Trial Pharmacy, National Cancer Center
Goyang-si, Gyeonggi-do 10408
2 trials
- NCT03395197Talazoparib + Enzalutamide vs. Enzalutamide Monotherapy in mCRPC
- NCT02684006A Study of Avelumab With Axitinib Versus Sunitinib In Advanced Renal Cell Cancer (JAVELIN Renal 101)
National Cancer Center
Ilsan, Gyeonggi-do 10408
2 trials
- NCT06773845Building Evidence for Ablative Internal Radiation Therapy in Localized HCC Beyond the Up-To-7 Criteria
  Contact: In Joon Lee, MD, PhD
- NCT06166576Radioembolization as a Spearhead Treatment of Hepatocellular Carcinoma With Localized Portal Vein Tumor Thrombosis
  Contact: In Joon Lee, MD, PhD
National Cancer Center
Ilsandong-gu, Goyang-si, Gyeonggi-do 10408
2 trials
- NCT06282575Efficacy and Safety of Zanidatamab With Standard-of-care Therapy Against Standard-of-care Therapy for Advanced HER2-positive Biliary Tract Cancer
  Contact: Clinical Trial Disclosure & Transparency
- NCT05580562ONC201 in H3 K27M-mutant Diffuse Glioma Following Radiotherapy (the ACTION Study)
  Contact: Heon Yoo, MD, PhD
National Cancer Center (NCC)
Goyang-si, Gyeonggi-do 10408
2 trials
- NCT04744831Trastuzumab Deruxtecan in Participants With HER2-overexpressing Advanced or Metastatic Colorectal Cancer
- NCT04215978Safety and Preliminary Effectiveness of BGB-A445 in Combination With Tislelizumab in Participants With Advanced Solid Tumors
National Cancer Center (Site 0702)
Goyang-si, Kyonggi-do 10408
2 trials
- NCT06997497A Clinical Study of Calderasib (MK-1084) With Targeted Therapy and Chemotherapy in People With Colorectal Cancer (MK-1084-012/KANDLELIT-012)
  Contact: Study Coordinator
- NCT03765918Study of Pembrolizumab Given Prior to Surgery and in Combination With Radiotherapy Given Post-surgery for Advanced Head and Neck Squamous Cell Carcinoma (MK-3475-689)
National Cancer Center (Site 1006)
Goyang-si, Kyonggi-do 10408
2 trials
- NCT03976362A Study of Pembrolizumab (MK-3475) With or Without Maintenance Olaparib in First-line Metastatic Squamous Non-small Cell Lung Cancer (NSCLC, MK-7339-008/KEYLYNK-008)
- NCT03976323Study of Pembrolizumab With Maintenance Olaparib or Maintenance Pemetrexed in First-line (1L) Metastatic Nonsquamous Non-Small-Cell Lung Cancer (NSCLC) (MK-7339-006, KEYLYNK-006)
National Cancer Center (Site 1354)
Goyang-si, Kyonggi-do 10408
2 trials
- NCT03924895Perioperative Pembrolizumab (MK-3475) Plus Cystectomy or Perioperative Pembrolizumab Plus Enfortumab Vedotin Plus Cystectomy Versus Cystectomy Alone in Participants Who Are Cisplatin-ineligible or Decline Cisplatin With Muscle-invasive Bladder Cancer (MK-3475-905/KEYNOTE-905/EV-303)
- NCT03924856Perioperative Pembrolizumab (MK-3475) Plus Neoadjuvant Chemotherapy Versus Perioperative Placebo Plus Neoadjuvant Chemotherapy for Cisplatin-eligible Muscle-invasive Bladder Cancer (MIBC) (MK-3475-866/KEYNOTE-866)
National Cancer Center (Site 2305)
Goyang-si, Kyonggi-do 10408
2 trials
- NCT06824467A Study to Evaluate the Efficacy and Safety of Sacituzumab Tirumotecan (MK-2870) Maintenance Treatment Versus Standard of Care in Participants With Platinum-sensitive Recurrent Ovarian Cancer (MK-2870-022/TroFuse-022/ENGOT-ov84/GOG-3103)
  Contact: Study Coordinator
- NCT06623422A Study of Pembrolizumab (MK-3475) With or Without Intismeran Autogene (V940) in Participants With Non-small Cell Lung Cancer (V940-009/INTerpath-009)
  Contact: Study Coordinator
National Cancer Center (Site 5202)
Goyang-si, Kyonggi-do 10408
2 trials
- NCT07513376A Clinical Trial of Adjuvant Intismeran (V940) With or Without Pembrolizumab Coformulated With Berahyaluronidase Alfa (MK-3475A) in High-Risk Stage I Non-Small Cell Lung Cancer (V940-014)
  Contact: Study Coordinator
- NCT06841354A Study of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) as Monotherapy and in Combination With Pembrolizumab (MK-3475) in Participants With Triple-Negative Breast Cancer (MK-2870-011/TroFuse-011)
  Contact: Study Coordinator
Center for Lung Cancer, National Cancer Center
Goyang-si, 10408
1 trial
- NCT06765109Neladalkib (NVL-655) for TKI-naive Patients With Advanced ALK-Positive NSCLC
  Contact: Ji-Youn Han, M.D., Ph.D. (principal investigator)
National Cancer Center
Gyeongin, 10408
1 trial
- NCT06319820A Study to Evaluate TAR-210 Versus Single Agent Intravesical Cancer Treatment in Participants With Bladder Cancer
National Cancer Center
Ilsandong, Goyang 10408
1 trial
- NCT04063527Phase III Trial of Stage I Ovarian Cancer After Surgery
  Contact: Sang Yoon Park
National Cancer Center
Kyeonggi-do
1 trial
- NCT06502743First-line Carboplatin and Paclitaxel in Combination With Pembrolizumab, Followed by Maintenance Pembrolizumab With or Without Nesuparib, in Patients With Newly Diagnosed Advanced or Recurrent MMR-proficient (pMMR) Endometrial Cancer
  Contact: Myoung Cheol Lim
National Cancer Center
Seogu, Busan 49201
1 trial
- NCT04306900TTX-030 in Combination With Immunotherapy and/or Chemotherapy in Subjects With Advanced Cancers
National Cancer Center - 3107
Goyang-si, 10408
1 trial
- NCT05671510ONC-392 Versus Docetaxel in Metastatic NSCLC That Progressed on PD-1/PD-L1 Inhibitors
National Cancer Center - Breast Cancer
Goyang, 10408
1 trial
- NCT06757634Phase 3 Study of Gedatolisib as First-Line Treatment for Patients With HR-Positive, HER2-Negative Advanced Breast Cancer (VIKTORIA-2)
  Contact: Nadene Zack, MS
National Cancer Center, Center for Breast Cancer
Goyang-si, Gyeonggi-do 10408
1 trial
- NCT01740427A Study of Palbociclib (PD-0332991) + Letrozole vs. Letrozole For 1st Line Treatment Of Postmenopausal Women With ER+/HER2- Advanced Breast Cancer (PALOMA-2)
National Cancer Center - Center For Prostate Cancer
Goyang-si, 10408
1 trial
- NCT03592472A Study of Pazopanib With or Without Abexinostat in Patients With Locally Advanced or Metastatic Renal Cell Carcinoma (RENAVIV)
  Contact: Sophia Paspal, Ph.D.
National Cancer Center /ID# 125602
Goyang, Gyeonggido 10408
1 trial
- NCT02163694A Phase 3 Randomized, Placebo-controlled Trial of Carboplatin and Paclitaxel With or Without Veliparib (ABT-888) in HER2-negative Metastatic or Locally Advanced Unresectable BRCA-associated Breast Cancer
National Cancer Center /ID# 204241
Goyang-si, Gyeonggido 10408
1 trial
- NCT03539536Study of Telisotuzumab Vedotin (ABBV-399) in Participants With Previously Treated c-Met+ Non-Small Cell Lung Cancer
National Cancer Center /ID# 231887
Goyang-si, Gyeonggido 10408
1 trial
- NCT04721015Study of Intravenous (IV) ABBV-637 Alone or in Combination With IV Docetaxel/Osimertinib to Assess Adverse Events and Change in Disease Activity in Adult Participants With Relapsed/Refractory (R/R) Solid Tumors
National Cancer Center /ID# 240169
Goyang, Gyeonggido 10408
1 trial
- NCT03639194A Study of ABBV-011 Alone and in Combination With Budigalimab (ABBV-181) in Participants With Relapsed or Refractory Small Cell Lung Cancer
National Cancer Center /ID# 241095
Goyang-si, Gyeonggido 10408
1 trial
- NCT03595059A Study With ABBV-155 Alone and in Combination With Taxane Therapy in Adults With Relapsed and/or Refractory Solid Tumors
National Cancer Center /ID# 248938
Goyang-si, Gyeonggido 10408
1 trial
- NCT05599984Study to Evaluate Adverse Events, Change in Disease Activity, and How ABBV-706 Moves Through the Body When Intravenously (IV) Infused Alone or in Combination With IV Infused Budigalimab, Cisplatin, or Carboplatin in Adult Participants With Advanced Solid Tumors
National Cancer Center /ID# 252290
Goyang-si, Gyeonggido 10408
1 trial
- NCT05005403Study to Assess Adverse Events and Pharmacokinetics in Adult Participants With Non-Small Cell Lung Cancer, Head and Neck Squamous Cell Carcinoma and Other Solid Tumors, Receiving Intravenous Infusion of Azirkitug Alone or in Combination(s) With Budigalimab, Bevacizumab, or Telisotuzumab Adizutecan
National Cancer Center /ID# 260663
Goyang-si, Gyeonggido 10408
1 trial
- NCT04928846A Study to Assess Disease Activity and Adverse Events of Intravenous (IV) Telisotuzumab Vedotin Compared to IV Docetaxel in Adult Participants With Previously Treated Non-Squamous Non-Small Cell Lung Cancer (NSCLC)
National Cancer Center /ID# 269481
Goyang-si, Gyeonggido 10408
1 trial
- NCT05445778Mirvetuximab Soravtansine With Bevacizumab Versus Bevacizumab as Maintenance in Platinum-sensitive Epithelial Ovarian, Fallopian Tube, or Peritoneal Cancer
National Cancer Center /ID# 270453
Goyang-si, Gyeonggido 10408
1 trial
- NCT06632951Study to Evaluate Adverse Events and Change in Disease Activity When Intravenously (IV) Infused Livmoniplimab is Used in Combination With IV Infused Budigalimab in Adult Participants With Urothelial Carcinoma (UC)
National Cancer Center /ID# 272265
Goyang-si, Gyeonggido 10408
1 trial
- NCT06682988A Study to Assess Adverse Events and Change in Disease Activity in Participants With Platinum-Resistant Advanced High-Grade Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancers With High Folate Receptor-Alpha Expression Treated With Intravenously (IV) Infused Mirvetuximab Soravtansine
National Cancer Center /ID# 276283
Goyang-si, Gyeonggido 10408
1 trial
- NCT07059845A Study to Assess Adverse Events and Change in Disease Activity of Multiple Treatment Combinations With Intravenous Mirvetuximab Soravtansine in Adult Participants With Ovarian Cancer
National Cancer Center /ID# 277353
Goyang-si, Gyeonggido 10408
1 trial
- NCT07155187A Study to Assess Adverse Events and Change in Disease Activity of Intravenous (IV) Telisotuzumab Adizutecan, Monotherapy or in Combination With Osimertinib, Compared to Standard of Care in Adult Participants With Locally Advanced or Metastatic EGFR-Mutated Non-Squamous Non-Small Cell Lung Cancer
National Cancer Center /ID# 277434
Goyang-si, Gyeonggido 10408
1 trial
- NCT07155174A Study to Evaluate the Optimal Dose, Adverse Events and Change in Disease Activity of Intravenous ABBV-706 in Combination With Atezolizumab Versus Standard of Care as First-Line Treatment in Adult Participants With Previously Untreated Extensive Stage Small Cell Lung Cancer
National Cancer Center (Site 0061)
Goyang-si, Kyonggi-do 10408
1 trial
- NCT03829319Safety and Efficacy Study of Pemetrexed + Platinum Chemotherapy + Pembrolizumab (MK-3475) With or Without Lenvatinib (MK-7902/E7080) as First-line Intervention in Adults With Metastatic Nonsquamous Non-small Cell Lung Cancer (MK-7902-006/E7080-G000-315/LEAP-006)
National Cancer Center (Site 0176)
Goyang-si, Kyonggi-do 10408
1 trial
- NCT03834519Study of Pembrolizumab (MK-3475) Plus Olaparib Versus Abiraterone Acetate or Enzalutamide in Metastatic Castration-resistant Prostate Cancer (mCRPC) (MK-7339-010/KEYLYNK-010)
National Cancer Center (Site 0196)
Goyang-si, Kyonggi-do 10408
1 trial
- NCT03898180Study of First-line Pembrolizumab (MK-3475) With Lenvatinib (MK-7902/E7080) in Urothelial Carcinoma Cisplatin-ineligible Participants Whose Tumors Express Programmed Cell Death-Ligand 1 and in Participants Ineligible for Platinum-containing Chemotherapy (MK-7902-011/E7080-G000-317/ LEAP-011)
National Cancer Center (Site 0304)
Goyang-si, Gyeonggi-do 10408
1 trial
- NCT03142334Safety and Efficacy Study of Pembrolizumab (MK-3475) as Monotherapy in the Adjuvant Treatment of Renal Cell Carcinoma Post Nephrectomy (MK-3475-564/KEYNOTE-564)
National Cancer Center (Site 0314)
Goyang-si, Kyonggi-do 10408
1 trial
- NCT03867084Safety and Efficacy of Pembrolizumab (MK-3475) Versus Placebo as Adjuvant Therapy in Participants With Hepatocellular Carcinoma (HCC) and Complete Radiological Response After Surgical Resection or Local Ablation (MK-3475-937 / KEYNOTE-937)
National Cancer Center (Site 0504)
Goyang-si, Kyonggi-do 10408
1 trial
- NCT07221474A Study of Intismeran Autogene (V940)/Placebo + Pembrolizumab and Chemotherapy in Metastatic Squamous Non-Small Cell Lung Cancer (V940-013)
  Contact: Study Coordinator
National Cancer Center (Site 0626)
Goyang-si, Kyonggi-do 10408
1 trial
- NCT04210115Study of Pembrolizumab (MK-3475) Versus Placebo in Participants With Esophageal Carcinoma Who Are Receiving Chemotherapy and Radiation Therapy (MK-3475-975/KEYNOTE-975)
National Cancer Center (Site 1002)
Goyang-si, Kyonggi-do 10408
1 trial
- NCT03631784A Trial of Pembrolizumab in Combination With Chemotherapy and Radiotherapy in Stage III NSCLC (KEYNOTE-799, MK-3475-799)
National Cancer Center (Site 1065)
Goyang-si, Kyonggi-do 10408
1 trial
- NCT04221945Study of Chemoradiotherapy With or Without Pembrolizumab (MK-3475) For The Treatment of Locally Advanced Cervical Cancer (MK-3475-A18/KEYNOTE-A18/ENGOT-cx11/GOG-3047)
National Cancer Center (Site 1800)
Goyang-si, Kyonggi-do 10408
1 trial
- NCT06966700A Clinical Study of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) in People With Breast Cancer (MK-2870-032)
  Contact: Study Coordinator
National Cancer Center (Site 2004)
Goyang-si, Kyonggi-do 10408
1 trial
- NCT06843447A Clinical Study of Raludotatug Deruxtecan in People With Ovarian Cancer (MK-5909-003).
  Contact: Study Coordinator
National Cancer Center (Site 2505)
Goyang-si, Kyonggi-do 10408
1 trial
- NCT07554339A Clinical Trial of Calderasib (MK-1084) and Durvalumab in People With Non-Small Cell Lung Cancer (MK-1084-015/KANDLELIT-015)
  Contact: Study Coordinator
National Cancer Center (Site # 2704)
Goyang-si, 10408
1 trial
- NCT06788990FORTIFI-HN01: A Study of Ficerafusp Alfa (BCA101) or Placebo in Combination With Pembrolizumab in First-Line PD-L1-pos, R or M HNSCC
  Contact: Principal Investigator
National Cancer Center (Site 2800)
Goyang-si, Kyonggi-do 10408
1 trial
- NCT04380636Study of Pembrolizumab With Concurrent Chemoradiation Therapy Followed by Pembrolizumab With or Without Olaparib in Stage III Non-Small Cell Lung Cancer (NSCLC) (MK-7339-012/KEYLYNK-012)
National Cancer Center (Site 2902)
Goyang-si, Kyonggi-do 10408
1 trial
- NCT07405151A Clinical Trial of Ifinatamab Deruxtecan in People With Advanced Esophageal Cancer (MK-3475-06F)
  Contact: Study Coordinator
National Cancer Center (Site 2905)
Goyang-si, Kyonggi-do 10408
1 trial
- NCT07216703A Clinical Study of Sacituzumab Tirumotecan (MK-2870) in Combination With Pembrolizumab (MK-3475) as First-line Maintenance Treatment of Cervical Cancer (MK-2870-036/TroFuse-036/GOG-3123/ENGOT-cx22)
  Contact: Study Coordinator
National Cancer Center (Site 3306)
Goyang-si, Kyonggi-do 10408
1 trial
- NCT04624204Placebo-controlled, Study of Concurrent Chemoradiation Therapy With Pembrolizumab Followed by Pembrolizumab and Olaparib in Newly Diagnosed Treatment-Naïve Limited-Stage Small Cell Lung Cancer (LS-SCLC) (MK 7339-013/KEYLYNK-013)
National Cancer Center (Site 3603)
Goyang-si, Kyonggi-do 10408
1 trial
- NCT07431827MK-3475A±Calderasib (MK-1084) in Completely Resected Stage IIA-IIIB (N2) KRAS G12Cm NSCLC (MK-1084-013)
  Contact: Study Coordinator
National Cancer Center (Site 3801)
Goyang-si, Kyonggi-do 10408
1 trial
- NCT06170788Sacituzumab Tirumotecan (MK-2870) in Combination With Pembrolizumab Versus Pembrolizumab Alone in Metastatic Non-small Cell Lung Cancer (NSCLC) With Programmed Cell Death Ligand 1 (PD-L1) Tumor Proportion Score (TPS) ≥ 50% (MK-2870-007)
  Contact: Study Coordinator
National Cancer Center (Site 3803)
Goyang-si, Kyonggi-do 10408
1 trial
- NCT06305754Sacituzumab Tirumotecan (MK-2870) Versus Pemetrexed and Carboplatin Combination Therapy in Participants With Epidermal Growth Factor (EGFR)-Mutated, Advanced Nonsquamous Non-small Cell Lung Cancer (NSCLC) Who Have Progressed on Prior EGFR Tyrosine Kinase Inhibitors (MK-2870-009)
National Cancer Center (Site 4065)
Goyang-si, Kyonggi-do 10408
1 trial
- NCT04634877Study of Pembrolizumab (MK-3475) in Combination With Adjuvant Chemotherapy With or Without Radiotherapy in Participants With Newly Diagnosed Endometrial Cancer After Surgery With Curative Intent (MK-3475-B21 / KEYNOTE-B21 / ENGOT-en11 / GOG-3053)
National Cancer Center (Site 4202)
Goyang-si, Kyonggi-do 10408
1 trial
- NCT04736706A Study of Pembrolizumab (MK-3475) in Combination With Belzutifan (MK-6482) and Lenvatinib (MK-7902), or Pembrolizumab/Quavonlimab (MK-1308A) in Combination With Lenvatinib, Versus Pembrolizumab and Lenvatinib, for Treatment of Advanced Clear Cell Renal Cell Carcinoma (MK-6482-012)
National Cancer Center (Site 9902)
Goyang-si, Kyonggi-do 10408
1 trial
- NCT06780111Substudy 06E: Umbrella Study of Combination Therapies in Esophageal Cancer (MK-3475-06E/KEYMAKER-U06)
  Contact: Study Coordinator
National Cancer Center,Substudy-01
Goyang, 410769
1 trial
- NCT05633667Study of Novel Treatment Combinations in Patients With Lung Cancer
National Cancer Center,Substudy-02
Goyang, 410769
1 trial
- NCT05633667Study of Novel Treatment Combinations in Patients With Lung Cancer
National Cancer Center,Substudy-03
Goyang, 410769
1 trial
- NCT05633667Study of Novel Treatment Combinations in Patients With Lung Cancer
National Cancer Centre
Goyang
1 trial
- NCT03133546Osimertinib and Bevacizumab Versus Osimertinib Alone as Second-line Treatment in Stage IIIb-IVb NSCLC With Confirmed EGFRm and T790M
National Cancer Centre
Goyang-si, Gyeonggi-do 10408
1 trial
- NCT04052971To Evaluate the Safety, Pharmacokinetics, Pharmacodynamics, and Antitumor Activity of ABN401 in Patients With Advanced Solid Tumors and Non-Small Cell Lung Cancer Harboring c-MET Dysregulation

Conditions

Diseases this institution publishes on or runs trials for.

Gastric and oesophageal cancer58 works · 32 trials
Ovarian cancer37 works · 31 trials
Neuromyelitis optica (NMOSD)17 works · 0 trials

Institution data: ROR 02tsanh21 (CC0-1.0)Updated 10 Nov 2026

Report an error